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Introduction
The main goal of juvenile idiopathic arthritis (JIA) treat-
ment is to achieve a long-term remission or, at least,
low levels of disease activity.
Objectives
To evaluate disease activity, focusing on achieving inactive
disease (ID) or minimal disease activity (MDA), based on
Juvenile Arthritis Disease Activity Score (JADAS) score,
after 5 years follow-up.
Methods
A cross sectional study at the 5th year of follow-up from
a JIA patients cohort, diagnosed between 2000-2008 was
carried out. Treatment strategy followed the Portuguese
recommendations for the treatment of JIA. The data
were collected using Reuma.pt (Portuguese Register of
Rheumatic Diseases). At the 5th year JADAS-27 was
evaluated and used to identify patients who met the pre-
liminary criteria for ID or MDA: score of 1 for ID and 2
and 3.8, for MDA, respectively, for patients with oligo
and polyarticular involvement. For applying the JADAS
score, children with rheumatoid factor (RF)-positive
polyarthritis, RF-negative polyarthritis, or extended oli-
goarthritis were included in the polyarthritis group and
the oligoarthritis group included children with persistent
oligoarthritis. Children with JIA that were classified in
the remaining ILAR categories were assigned to the poly
or oligoarthritis group based on the number of joints
affected during disease course (>4 or <4, respectively).
Cutoffs for acceptable symptom state ranged from 3.2 to
5.4 for parents.
Results
Eighty one JIA patients were identified with a follow-up
of at least 5 years. Fourteen patients were excluded due
to loss for follow-up and 2 developed criteria for systemic
erythematous lupus. Forty four were female (68%),
mean age at diagnosis 7.7 ± 4.9 years and mean follow-up
7.6 ± 2.6 years (minimum 5, maximum 13). From the
65 patients, 28(43.1%) had persistent oligoarthritis, 11
(16.9%) RF-negative polyarthritis, 11(16.9%) enthesitis
related arthritis, 8(12.3%) extended oligoarthritis, 3(4.6%)
RF-positive polyarthritis, 2(3.1%) psoriatic arthritis and
2(3.1%) systemic JIA. Seventy three percent were on meth-
otrexate, 11% on sulphasalazine and 23% on biologics
(53%etanercept, 20%adalimumab, 20%Infliximab, 7%ana-
kinra). At the 5th year the mean JADAS was 0.78 for
persistent oligoarthritis, 2.1 for extended oligoarthritis, 4.8
for RF-positive polyarthritis, 5.4 for RF-negative polyar-
thritis, 0.75 for psoriatic arthritis, 0.5 for enthesitis related
arthritis and 0.3 for systemic JIA. In our population 68%
had ID criteria at the 5th year after diagnosis and 7.7%
had MDA. From those patients who had ID criteria,
50% had achieved that status after 2 years of follow-up
and 81% after 3 years. From the 11 cases who had neither
ID nor MDA, 7 were poly JIA (4 RF negative and 3
positive). All of them except 3 had acceptable symptoms
stated by the parents.
Conclusion
At the 5th year of follow-up, with current management
strategies in daily clinical practice, around 68% of our
JIA patients had achieved ID by JADAS criteria. However,
for almost 17% of the patients (mostly of the polyarticular
subtype), the current treatment strategies were insufficient
to reach this goal, suggesting that these patients need a
more aggressive treatment strategy.
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